Melbourne (Australia) and Dresden (Germany) | 19 March 2024

Telix today announces that it has entered into an agreement to commercially partner the QDOSE® dosimetry software platform with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH (ABX-CRO), a full-service contract research organisation (CRO) based in Dresden, and its development partner, Stockholm-based Quantinm AB.

QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals. Telix intends to integrate the QDOSE® platform into its therapeutic radiopharmaceutical programs and clinical collaborations to enable the development of personalised treatment regimens. Personalised radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimising treatment response while reducing effects on normal healthy organs and optimising the use of isotope supply chains.

QDOSE® supports dosimetry calculations using planar imaging, tomographic imaging, single/multi time point imaging and hybrid combinations. QDOSE® incorporates additional tools for attenuation and background correction. The QDOSE® platform will be integrated with Telix’s artificial intelligence (AI) products as an accessible tool for clinicians and third-party commercial drug developers. QDOSE® has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is Conformité Européenne (CE) marked for clinical use within the European Union (EU).

Dr Christian Behrenbruch, Managing Director and Group CEO of Telix said, “In nuclear medicine, dosimetry analysis is used to calculate the absorbed dose of radiation received by different parts of the body. Rapid, reliable and personalised dosimetry is becoming an increasingly important future direction of cancer care and regulatory authorities now expect to see dosimetry analysis. QDOSE® has an excellent performance track record and we are committed to positioning QDOSE® as a new industry standard in dosimetry analysis.”

The arms’ length up-front transaction consideration is non-material. Telix will pay undisclosed product royalties and fees on product sales.

To read the full media release click here